Cargando…

Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer

BACKGROUND: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bounaix Morand du Puch, Christophe, Nouaille, Michelle, Giraud, Stéphanie, Labrunie, Anaïs, Luce, Sandrine, Preux, Pierre-Marie, Labrousse, François, Gainant, Alain, Tubiana-Mathieu, Nicole, Le Brun-Ly, Valérie, Valleix, Denis, Guillaudeau, Angélique, Mesturoux, Laura, Coulibaly, Béma, Lautrette, Christophe, Mathonnet, Muriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721000/
https://www.ncbi.nlm.nih.gov/pubmed/26791256
http://dx.doi.org/10.1186/s12967-016-0765-4
_version_ 1782411157483552768
author Bounaix Morand du Puch, Christophe
Nouaille, Michelle
Giraud, Stéphanie
Labrunie, Anaïs
Luce, Sandrine
Preux, Pierre-Marie
Labrousse, François
Gainant, Alain
Tubiana-Mathieu, Nicole
Le Brun-Ly, Valérie
Valleix, Denis
Guillaudeau, Angélique
Mesturoux, Laura
Coulibaly, Béma
Lautrette, Christophe
Mathonnet, Muriel
author_facet Bounaix Morand du Puch, Christophe
Nouaille, Michelle
Giraud, Stéphanie
Labrunie, Anaïs
Luce, Sandrine
Preux, Pierre-Marie
Labrousse, François
Gainant, Alain
Tubiana-Mathieu, Nicole
Le Brun-Ly, Valérie
Valleix, Denis
Guillaudeau, Angélique
Mesturoux, Laura
Coulibaly, Béma
Lautrette, Christophe
Mathonnet, Muriel
author_sort Bounaix Morand du Puch, Christophe
collection PubMed
description BACKGROUND: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving yet sufficient reliability for recommended use in the clinical routine. METHODS: We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standardized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of percentiles to assess sensitivity, specificity and concordance. RESULTS: We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below-average specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and patients’ responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treatment switch over a longer time course, demonstrated improvement in specificity and concordance. CONCLUSIONS: Results establish feasibility and usefulness of the Oncogramme, prelude to a larger-scale trial. Advantages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of methods available to clinicians to individualize treatments and improve patient prognosis. Trial registration: ClinicalTrials.gov database, registration number: NCT02305368 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-0765-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4721000
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47210002016-01-22 Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer Bounaix Morand du Puch, Christophe Nouaille, Michelle Giraud, Stéphanie Labrunie, Anaïs Luce, Sandrine Preux, Pierre-Marie Labrousse, François Gainant, Alain Tubiana-Mathieu, Nicole Le Brun-Ly, Valérie Valleix, Denis Guillaudeau, Angélique Mesturoux, Laura Coulibaly, Béma Lautrette, Christophe Mathonnet, Muriel J Transl Med Research BACKGROUND: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving yet sufficient reliability for recommended use in the clinical routine. METHODS: We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standardized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of percentiles to assess sensitivity, specificity and concordance. RESULTS: We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below-average specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and patients’ responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treatment switch over a longer time course, demonstrated improvement in specificity and concordance. CONCLUSIONS: Results establish feasibility and usefulness of the Oncogramme, prelude to a larger-scale trial. Advantages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of methods available to clinicians to individualize treatments and improve patient prognosis. Trial registration: ClinicalTrials.gov database, registration number: NCT02305368 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-0765-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-12 /pmc/articles/PMC4721000/ /pubmed/26791256 http://dx.doi.org/10.1186/s12967-016-0765-4 Text en © Bounaix Morand du Puch et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bounaix Morand du Puch, Christophe
Nouaille, Michelle
Giraud, Stéphanie
Labrunie, Anaïs
Luce, Sandrine
Preux, Pierre-Marie
Labrousse, François
Gainant, Alain
Tubiana-Mathieu, Nicole
Le Brun-Ly, Valérie
Valleix, Denis
Guillaudeau, Angélique
Mesturoux, Laura
Coulibaly, Béma
Lautrette, Christophe
Mathonnet, Muriel
Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
title Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
title_full Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
title_fullStr Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
title_full_unstemmed Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
title_short Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
title_sort chemotherapy outcome predictive effectiveness by the oncogramme: pilot trial on stage-iv colorectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721000/
https://www.ncbi.nlm.nih.gov/pubmed/26791256
http://dx.doi.org/10.1186/s12967-016-0765-4
work_keys_str_mv AT bounaixmoranddupuchchristophe chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT nouaillemichelle chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT giraudstephanie chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT labrunieanais chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT lucesandrine chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT preuxpierremarie chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT labroussefrancois chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT gainantalain chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT tubianamathieunicole chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT lebrunlyvalerie chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT valleixdenis chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT guillaudeauangelique chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT mesturouxlaura chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT coulibalybema chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT lautrettechristophe chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer
AT mathonnetmuriel chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer